Back in April 2024, I assigned Day One Biopharmaceuticals, Inc. (DAWN) stock a "Hold" rating in a note for the Seeking Alpha, covering the news that its lead asset tovorafenib had been awarded an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results